Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of rituximab + high-dose methotrexate + orelabrutinib in newly diagnosed elderly primary CNS lymphoma
ChiCTR2200056290Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate and orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: Objective response rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
rituximabmethotrexateorelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2200056290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056290.